Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML.

ABSTRACT:

Background

Second-generation FLT3-inhibitors (FLT3i) demonstrated single-agent composite CR rates (CRc) of 45-55% in patients with relapsed/refractory (R/R) FLT3-mutated AML in phase II/III trials. However, > 85% of patients treated were prior FLT3i naïve. The response rates to sequential FLT3i exposure remain poorly defined.

Methods

We retrospectively reviewed patients with FLT3-mutated AML between November 2006 and December 2019.

Results

In frontline patients treated with a FLT3i (cohort 1), the CRc rates and median overall survival (OS) with the first (n = 56), second (n = 32), and third FLT3i-based (n = 8) therapy were 77%, 31%, and 25%, and 16.7 months, 6.0 months, and 1.4 months, respectively. In patients receiving a FLT3i-based therapy for the first time in a R

SUBMITTER: Yilmaz M 

PROVIDER: S-EPMC7542942 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature